DAVID
HELLERSTEIN, MD
PSYCHIATRY
PRACTICE
RESEARCH
OFFICE
LOCATION
PRACTICE
POLICIES
ABOUT
DR.
HELLERSTEIN
LINKS
WRITING
BOOKS
LITERARY
WRITING
ABOUT
DAVID
HELLERSTEIN
PUBLICATIONS
EXCERPTS
LINKS
Books available at:
Amazon.com
Backinprint.com
E-Mail
Contact:
djhell@aol.com
Mailing
Address:
135 Central Park West
Suite #aB
New York, NY 10023
|
© 2000, David
Hellerstein
David Hellerstein,
M.D.
Psychiatrist and Writer
|
RESEARCH
Dr. Hellerstein is Director of the
Mood Disorders Research Unit at St. Lukes-Roosevelt Hospital Center in New York, NY. This outpatient research
center enrolls subjects for studies on a variety of medications, both established
and new treatments. It has participated in pioneering studies in areas
including:
· the treatment of dysthymia (chronic
depression),
· the treatment of bipolar depression
and bipolar mania,
· the combination of psychotherapy
and pharmacotherapy for treatment of depression
SCIENTIFIC
PUBLICATIONS
Dr. Hellerstein has published
over 30 articles and book chapters, and over 40 abstracts in scientific journals
and professional organizations proceedings. Journals include: American
Journal of Psychiatry, Archives of General Psychiatry, Journal of Psychotherapy
Practice and Research, Hospital and Community Psychiatry, Journal of Serotonin
Research, Progress in Neuropsychopharmacology and Biological Psychiatry,
Journal of Clinical Psychiatry, and CNS Drugs. Dr. Hellerstein
has made many presentations at national and international conferences.
SELECTED
SCIENTIFIC PUBLICATIONS
1) Rosenthal RN, Hellerstein DJ, Miner CR: A model of integrated services
for outpatient treatment of patients with comorbid schizophrenia and addictive
disorders. American Journal on Addictions 1992;1:339-348
2) Rosenthal RN, Hellerstein DJ, Miner CR: Integrated services for treatment
of schizophrenic substance abusers: demographics, symptoms and substance
abuse patterns. Psychiatric Quarterly 1992;63:3-26
|
3) Hellerstein
DJ, Yanowitch P, Rosenthal J, Samstag LW, Maurer M, Kasch K, Burrows L, Poster
M, Cantillon M, Winston A: A randomized double-blind study of fluoxetine
versus placebo in treatment of dysthymia. American Journal of Psychiatry
1993; 150: 1169-1175
4) Hellerstein DJ, Rosenthal RN, Miner CR: Integrated outpatient treatment
for substance-abusing schizophrenics: a prospective study. American Journal
on Addictions 1995;4:33-42
5) Hellerstein DJ, Rosenthal RN, Pinsker H: Supportive therapy as the treatment
model of choice. The Journal of Psychotherapy Practice and Research
1994;3:300-306
6) Kocsis JH, Zisook S, Davidson J, Shelton R, Yonkers K, Hellerstein DJ,
Rosenbaum J, Halbreich U: Double-blind comparison of sertraline, imipramine,
and placebo in the treatment of dysthymia: psychosocial outcomes. American
Journal of Psychiatry 1997;154:390-395
7) Miner CR, Rosenthal RN, Hellerstein DJ: Through the revolving door: prediction
of dropout in substance-abusing schizophrenic patients in outpatient group
treatment, Archives of General Psychiatry 1997;54:706-712
8) Hellerstein DJ, Rosenthal RN, Pinsker H, Samstag LW, Muran JC, Winston
A: A randomized prospective study comparing supportive and dynamic therapies:
outcome and alliance. Journal of Psychiatric Practice and Research 1998;7:261-271
|
|
